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Abstract
Background: The immune process driving eosinophilic and non-eosinophilic asthma is likely driven by different subsets of T
helper (Th) cells. Recently, in vitro studies and animal studies suggest that Th cell subsets displays plasticity by changing
their transcription factor or by expressing multiple transcription factors. Our aim was to determine whether individuals with
asthma and elevated circulating eosinophils express signs of different regulatory immune mechanisms compared with
asthmatics with low blood eosinophils and non-asthmatic control subjects. In addition, determine the relationship between
eosinophilia and circulating Th cell subsets.
Methodology/Principal findings: Participants were selected from a random epidemiological cohort, the West Sweden
Asthma Study. Immunophenotypes of fresh peripheral blood cells obtained from stable asthmatics, with and without
elevated eosinophilic inflammation (EOS high and EOS low respectively) and control subjects, were determined by flow
cytometry. No differences in the number of Th1 (T-bet), Th2 (GATA-3), Th17 (RORct) or Treg (FOXP3) cells were observed
between the groups when analysing each subset separately. However, in all groups, each of the Th subsets showed
expression of additional canonical transcription factors T-bet, GATA-3, RORct and FOXP3. Furthermore, by in vitro
stimulation with anti-CD3/anti-CD28 there was a significant increase of single expressing GATA-3
+ and co-expressing T-
bet
+GATA-3
+ cells in the EOS high asthmatics in comparison with control subjects. In addition, T-bet
2GATA-
3
+RORct
+FOXP3
+ were decreased in comparison to the EOS low asthmatics. Finally, in a group of control subjects we
found that the majority of proliferating Th cells (CD4
+CD25
+Ki67
+) expressed three or four transcription factors.
Conclusions: The ability of human Th cells to express several regulatory transcription factors suggests that these cells may
display plasticity in vivo.
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Introduction
Asthma is a heterogeneous disease; patients express different
phenotypes and have differences in severity, natural history, and
response to treatment [1–3]. It has been suggested that asthmatics
can be divided into several subgroups, each with characteristic
asthma symptoms that arise from distinct pathological processes
[4]. A recent publication proposed that a subtype of asthma with a
distinct underlying pathology can be classed as an ‘‘endotype’’ [5].
Cluster analysis of asthma phenotypes has identified distinct
subgroups of patients, some of which have eosinophilic inflam-
mation [2]. Phenotyping studies on these groups of asthmatics may
shed some light on the immunological processes underlying these
phenotypically-distinct disease subtypes and help to identify and
characterise asthma endotypes.
In addition to the well characterised T regulatory (Tregs) cells
and T helper (Th) cells, such as Th1 and Th2, new effector cells,
including Th17, Th9 and Th22 have been identified in the last few
years [6]. Until recently, Th effector cells were considered to be
fully differentiated, with a permanent function upon expression of
a characteristic transcription factor and their development from
naı ¨ve CD4 cells was thought to be lineage specific [7]. However,
there is accumulating evidence from animal models and in vitro
studies to suggest that Th cell subsets are not irreversibly
differentiated, but can exhibit plasticity by changing transcription
factor expression or by expressing multiple transcription factors
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40012[8–12]. This plasticity of T cell differentiation has recently been
suggested to play a role in modulating inflammatory disease
[8,13]. To date, this evidence has mainly come from experimental
studies [14–18]; however, it raises the question of whether the
same phenomenon occurs in circulating T cells in healthy humans
and/or asthmatics.
Our hypothesis was that patients with a specific asthma
endotype could be distinguished by the immunological profile of
their circulating Th cells. Therefore, we compared the absolute
numbers of circulating Th cells expressing the transcription
factors, T-bet, GATA-3, RORct and FOXP3, in two groups of
asthmatics. All participants, both asthmatics and healthy subjects,
were selected from an epidemiologically based asthma cohort
study, the West Sweden Asthma Study. The asthmatics displayed
similar clinical disease profiles, but with distinct differences in the
number of circulating eosinophils, and were compared to healthy
subjects.
Materials and Methods
Study Subjects
Study participants were selected from questionnaire respondents
in the West Sweden Asthma Study (aged 16–75 years) who
attended a detailed clinical examination at the Krefting Research
Centre, Gothenburg, Sweden and for whom clinical data was
available (Visit 1) [19]. Study participants attending Visit 1 and
fulfilling inclusion criteria described below, were invited to
participate in the study. Asthma was diagnosed from reports of
common symptoms and a PD20 for methacholine below a
cumulative dose of 1.94 mg or a FEV1 reversibility greater than
12%. The skin prick test (SPT) was performed using a standard
panel of 11 inhalant allergens composed of birch, mugwort,
timothy, horse, dog, cat, cockroach, Cladosporium, Alternaria,
Dermatophagoides farinae and D. pteronyssinus (ALK, Hørsholm,
Denmark). The SPT test was considered positive with a wheal
and flare reaction $3mm for at least one allergen. Asthmatics
were considered to have high numbers of eosinophils if blood
eosinophils were $0.3610
9/L and low eosinophils if values were
#0.2610
9/L. Control subjects did not report asthma symptoms,
were non-reactive to methacholine or non-reversible, were SPT
negative and had a low number of blood eosinophils. All
participants were non-smokers.
The study population consisted of 11 asthmatics with high blood
eosinophils (EOS high group), 12 asthmatics with low blood
eosinophils (EOS low group) and 9 non-asthmatic healthy controls
(control group). Participants were recruited in two separate blocks
either during winter time (December to February) or during spring
time (April to early June). During a clinical visit (Visit 2) blood
samples, nasal lavage (NAL) and induced sputum were collected in
addition to spirometry and fractional exhaled nitric oxide (FeNO)
measurements were taken. During four weeks prior to Visit 2,
none of the subjects had received any vaccination, changed their
asthma medication, had any worsening of asthma symptoms,
reported any symptoms of infection/cold, had any surgery, had
any antibiotics, had any new medication, or had any anti-
inflammatory medication (i.e. NSAIDs). The time period separat-
ing Visit 1 and Visit 2 ranged between 3 months to 2 years.
All subjects gave written informed consent. None of the
participants of this study were under the age of eighteen. Ethical
approval for the study was granted by the Regional Ethical
Approval Committee in Gothenburg, Sweden (no. 593-08).
Cells and Immunostaining
Peripheral whole blood cells were stained for flow cytometry
within 1 hour of sampling. The total cell count was obtained using
Trucount
TM tubes (BD Biosciences, San Jose, CA, USA) together
with antibodies (Ab) detecting CD45/CD3/CD4 or CD45/CD3/
CD4/CD14/CD19 according to manufacturer’s protocol. Addi-
tionally, the following Ab panels were used: a) CD4/CD25/T-bet/
GATA-3/RORct/FOXP3 with or without CD3, b) CD45RO/
CD45RA/CD3/T cell receptor (TCR)ab/TCRcd/CD4/CD8, c)
CD45/CD56/CD16/CD19/CD14, d) CD4/CD25/Ki-67/T-
bet/GATA-3/RORct and e) CD4/CD25/Ki-67/T-bet/
RORct/FOXP3. All monoclonal antibodies were purchased from
BD Biosciences, eBioscience or Invitrogen (detailed in Table S3). A
Foxp3 Staining Buffer Set (eBioscience, Inc. San Diego, CA, USA)
was used according to manufacturer’s protocol for all intracellular
staining.
Human peripheral blood mononuclear cells (PBMCs) were
isolated by density centrifugation using Ficoll-Paque
TM (GE
Healthcare Bio-Sciences, Uppsala, Sweden) and cultured in
serum-free AIM-VH + AlbuMAXH medium (Invitrogen, GIBCO,
Grand Island, NY, USA) alone or in plates pre-coated with anti-
CD3/anti-CD28 antibodies (1 mg each/mL; BD Pharmingen
TM,
BD Biosciences) for 48 hours, before flow cytometry staining with
antibody panel A (see above). Cell viability was analysed using
7AAD exclusion in the forward scatter-side scatter (FSC-SSC)
gate. Cell viability was .96% (range 96.3–99.1%) in cells
harvested from medium alone and .88% (range 88.4–95.8%) in
cells harvested from anti-CD3/anti-CD28 coated wells.
Flow Cytometry
Samples were processed on a BD FACS Aria (BD Biosciences,
San Jose, CA, USA) and data were analyzed with FlowJo software
(Tree Star, Ashland, OR). Gating of transcription factors and
surface markers were determined using control samples by the
Fluorescence Minus One (FMO) approach i.e. controls containing
all markers except the one of interest were used to set gates
(Figure S1).
Cytospin Preparations and Microscopy
Cells from induced sputum and NAL were stained with May-
Gru ¨nwald and Giemsa (HistoLab Products AB, Gothenburg,
Sweden) and counted using a Zeiss Axioplan microscope (Carl
Zeiss Jena GmbH, Eching, Germany; Methods S1).
CD4 T lymphocytes were enriched from PBMCs according to
the manufacturer’s protocol (Human CD4 T Lymphocyte
Enrichment Set, BD IMag
TM, BD Pharmingen
TM, BD Biosci-
ences) and stained with the following combinations: a) T-bet/
GATA-3, b) FOXP3/GATA-3, c) T-bet/RORct and d) FOXP3/
RORct. The detection signal was enhanced using fluorochrome-
conjugated secondary antibodies (Table S3). Cytospins were made
after completion of the staining procedure and mounted with
ProLongH Gold antifade reagent with DAPI (Invitrogen
TM,
Molecular ProbesH, Eugene, OR, USA). Images were captured
with a Zeiss LSM 510 META microscope using Zeiss LSM 510
software (Carl Zeiss MicroImaging GmbH, Germany). Confocal
images are made by Z sectioning at scale 0.38 mm. Technical
controls are shown in figure S2.
Statistical Analyses
Data were tested for adherence to a normal distribution with the
Kolmogorov-Smirnov test (with Dallal-Wilkinsson-Lilliefor cor-
rected P value). If a normal distribution of sample means could be
assumed, unpaired test or paired t-test was used; otherwise the
Asthma and T Cell Plasticity
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e40012Kruskal-Wallis test followed by the Mann-Whitney U test were
applied. Values in tables and graphs are mean6SEM, except in
scatter plot graphs where median values are given. Correlations
were performed using Pearson correlation test. Values of p,0.05
were considered statistically significant.
Results
Eosinophilia
Clinical characteristics and standard hospital laboratory mea-
surements were similar between the study groups, except for a
higher number of eosinophils in the blood in the EOS high group
compared with the EOS low and control groups (p,0.001;
Table 1). No differences were observed between the groups in
either the numbers of any general T cell population, CD3/CD4/
CD8, their memory/naı ¨ve subpopulations or TCRcd cells.
However, TCRab cells showed increased numbers in the EOS
high group compared to the EOS low group of asthmatics.
Furthermore, the number of monocytes, natural killer (NK) and B
cells were similar between the three groups (Table S1). The
relative number of eosinophils in induced sputum was significantly
higher in the EOS high group compared with the healthy controls
(p,0.05) and higher in comparison to the EOS low group,
although the difference was not significant (Table 1).
Th Cell Transcription Factors
The number of CD4
+CD25
+ cells and the expression of the
transcription factors T-bet, GATA-3, RORct and FOXP3 was
analysed in the groups. The total number of CD4
+CD25
+ T cells
did not differ between the groups (Table S1). The levels of
transcription factors are presented in Figure 1. There were no
differences in the numbers of T-bet
+, GATA-3
+, RORct
+ or
Table 1. Demographic and clinical characteristics of study participants.
Parameter Units Healthy controls Asthmatics EOS High Asthmatics EOS Low
mean (±SEM) mean (±SEM) mean (±SEM)
No. of participants M/F 6/3 4/7 6/6
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
Age years 37.9 (3.6) 39.0 (3.6) 38.7 (3.4) 40.1 (3.4) 39.8 (2.5) 40.9 (2.5)
BMI 24.2 (0.7) 26.3 (1.8) 27.3 (1.6)
FeNO ppb 15.9 (1.8); n=7 16.8 (2.2) 48.4 (13.6); n=9 28.1 (6.6) 23.8 (3.8) 22.2 (4.8)
FEV1, predicted % 102.1 (4.4) 94.5 (3.1); n=8 99.4 (3.1) 94.2 (4.1) 94.7 (3.7) 88.4 (4.6); n=11
FEV1 reversibility % 6.3 (1.2) 12.6 (4.5); n=10 7.5 (2.1)
""
Methacholine, PD20 mg
" 268.8 (126.7) 613.7 (131.5); n=11
C-reactive protein mg/L 3.0 (1.9) 2.3 (0.8) 1.4 (0.6)
Blood eosinophils x10
9/L 0.12 (0.02) 0.13 (0.02) 0.37 (0.03){*** 0.32 (0.03){*** 0.10 (0.01) 0.14 (0.02)
Blood neutrophils x10
9/L 3.26 (0.25) 3.78 (0.42) 3.36 (0.28) 3.48 (0.31) 3.35 (0.28) 3.42 (0.34)
Blood basophils x10
9/L 0.01 (0.01) 0.01 (0.01) 0.05 (0.02) 0.04 (0.02) 0.02 (0.01) 0.01 (0.01)
Blood monocytes x10
9/L 0.38 (0.05) 0.39 (0.05) 0.47 (0.04) 0.40 (0.05) 0.40 (0.03) 0.35 (0.03)
Blood lymphocytes x10
9/L 1.94 (0.13) 1.98 (0.20) 1.99 (0.12) 2.27 (0.15) 1.82 (0.09) 2.04 (0.17)
Sputum eosinophils % of total cells 0.70 (0.35); n=8 7.62 (2.89){{* 1.80 (0.58); n=11
NAL eosinophils % of total cells 0.96 (0.40); n=8 3.87 (1.45); n=10 1.54 (1.01)
Skin prick test +/2 0/9 8/3 9/3
Medication
Inhaled steroids
""" Y e s 004451
N o 993449
Intermittently 0 0 3 3 3 2
b2-agonist
"""" Y e s 003201
N o 991166
Intermittently 0 0 7 8 6 5
Combination
medication
"""""
Y e s 001100
N o 99981 0 1 0
Intermittently 0 0 1 2 2 2
"Non-reactive to methacholine up to a dose of 1.96 mg.
""One individual, not subjected to methacholine, was selected based on FEV1 reversability with a value of 25%.
"""Budesonide 400 mg/day at visit 2for all users, except one individual in EOS low group with a usage of 200 mg/day.
""""Short acting b2-agonist is most frequently used.
"""""Budesonide 320 mg/day at visit 2 for all users.
{Statistically significant in comparison with EOS low and healthy controls (***P,0.001).
{{Statistically significant in comparison with healthy controls (*P,0.05).
doi:10.1371/journal.pone.0040012.t001
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+ cells between the groups when analysing each subset
separately (Figure 1A-D).
Analysis of Th Cells Expressing Multiple Master
Regulatory Transcription Factors
In addition to quantifying the different Th cell subsets, the
number of cells co-expressing the transcription factors T-bet,
GATA-3, RORct and FOXP3 as measured in each subset of Th
cells (Figure 2). Cells expressing only FOXP3 were increased in the
EOS high group compared with healthy controls (p,0.05; Figure 2
D). In some cell subtypes, up to four transcription factors were co-
expressed but none of the co-expressing subtypes showed any
significant difference between groups.
To confirm the flow cytometry data of co-expression of
transcription factors in CD4
+ cells, confocal microscopy was
performed. CD4
+ cells from the peripheral blood of a control
subject and an asthmatic individual with elevated blood eosino-
phils were enriched and immunostained using the same clones of
primary antibodies used for flow cytometric staining, but with the
addition of fluorochrome conjugated secondary antibodies. This
technique enabled the visualisation of the expression of two
transcription factors in the same sample, specifically, T-bet/
GATA-3 (Figure 3A+B, ex vivo), T-bet/RORct (Figure 3C+D, ex
vivo), FOXP3/GATA-3 (Figure 3E+F, ex vivo) and FOXP3/
RORct (Figure 3G+H, ex vivo).
In vitro Stimulation Increases the Number of Cells
Expressing Multiple Transcription Factors
Todetermineifinvitrostimulationofthecellscouldchangetheco-
expression pattern of transcription factors, PBMCs taken from all
groupsduringwintertimewereculturedwithacombinationofanti-
CD3andanti-CD28antibodies.After48hours,cellswereharvested
and stained for co-expression of T-bet, GATA-3, RORct and
FOXP3. The number of cells expressing multiple and single
transcription factors was expressed as a percentage of the total
CD4
+ T cell count and the effect of stimulation compared with
medium alone. A sub analysis showed that most Th subsets
increased after stimulation compared to medium alone but not all
(Table 2). Single FOXP3
+ and T-bet
+FOXP3
+ cells were not
increased in any group. Single T-bet
+ and GATA-3
+FOXP3
+ cells
wereonlyincreasedinEOShighgroup.RORct
+FOXP3
+cellswere
only increased in the asthmatic groups. To compare between
groups, the fold change was calculated by dividing the number of
cells obtained from stimulated samples by the number of cells
Figure 1. Transcription factors expressed by T cell subtypes. Numbers of Th subtypes expressing the transcription factors T-bet (Th1; A),
GATA-3 (Th2; B) RORct (Th17; C) and FOXP3 (Treg; D) in the control (healthy non-asthmatics, n=9), EOS high (asthmatics with elevated blood
eosinophils, n=11), and EOS low (asthmatics with low blood eosinophils, n=12) groups. The horizontal line represents the median of the group.
Filled symbols represent samples obtained in the winter time, while open symbols represent samples obtained during spring time.
doi:10.1371/journal.pone.0040012.g001
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differedbetweenthegroups;singleGATA-3
+cellswereincreasedin
the EOS high group in comparison to controls, T-bet
+GATA-3
+
cells were increased in both asthmatic groups and GATA-
3
+RORct
+FOXP3
+ cells were decreased in the EOS high group
compared to the EOS low group (Figure 4). Non-specific cell
stimulation without the addition of exogenous polarising cytokines
can thus increase the number of cells co-expressing multiple master
Figure 2. Sub analysis of circulating T-helper cell subtypes. Numbers of each subtype in the control (healthy non-asthmatics, n=9), EOS high
(asthmatics with elevated blood eosinophils, n=11), and EOS low (asthmatics with low blood eosinophils, n=12) groups. CD4
+CD25
+ cells positive
for only one of the transcription factors T-bet
+ (A), GATA-3
+ (B), RORct
+ (C) and FOXP3
+ (D). CD4
+CD25
+ cells co-expressing two transcription factors
T-bet
+GATA-3
+ (E), T-bet
+RORct
+ (F), T-bet
+FOXP3
+ (G), GATA-3
+RORct
+ (H), GATA-3
+FOXP3
+ (I) and RORct
+FOXP3
+ (J). CD4
+CD25
+ cells positive for
three transcription factors T-bet
+GATA-3
+RORct
+ (K), T-bet
+GATA-3
+FOXP3
+ (L), T-bet
+RORct
+FOXP3
+ (M) and GATA-3
+RORct
+FOXP3
+ (N). CD4
+CD25
+
cells expressing all four transcription factors T-bet
+GATA-3
+RORct
+FOXP3
+ (O). The horizontal line represents the median of the group. *p,0.05.
Filled symbols represent samples obtained in the winter time, while open symbols represent samples obtained during spring time.
doi:10.1371/journal.pone.0040012.g002
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cells,indicatingthatthisisanactiveprocess.Thisco-expressiondata
was confirmed by repeating the confocal microscopy on CD4
+ cells
enriched from cultured PBMCs as previously mentioned above.
Micrographs showed co-expression of T-bet/GATA-3
(Figure 3A+B, in vitro), T-bet/RORct (Figure 3C+D, in vitro), and
FOXP3/GATA-3 (Figure 3E+F, in vitro) and FOXP3/RORct
(Figure 3G+H, in vitro) in CD4
+ cells both from stimulated cells as
wellasinmediumalonetreatedcells.However,inthemediumalone
treated samples, co-expressing cells were fewer overall than in the
stimulated samples.
Proliferating Th Cells Express Multiple Transcription
Factors
Data on subsets of Th cells in circulation that are proliferating
are shown in figure 5. Proliferating cells are cells positive of the
marker Ki-67. Two different Ab panels, Panel D (CD4/CD25/Ki-
67/T-bet/GATA-3/RORct) and Panel E (CD4/CD25/Ki-67/
T-bet/RORct/FOXP3) were used, since only three different
transcription factors in addition to Ki-67 could be evaluated
simultaneously. Therefore, we present the data as more or equal to
three transcription factors ($3TFs) in figure 5B and 5C. In a
group of healthy controls (n=5) we found that 8.44% of
CD4
+CD25
+ cells in Panel D and 7.44% of CD4
+CD25
+ cells
in Panel E comprise of Ki-67
+ cells (Figure 5A). Most of the Ki-67
+
cells were co-expressing the three transcriptions factors in each of
the Ab panels (Panel D 72.4466.21%; Panel E 70.4167.29%;
Figure 5B). On the contrary, we found that in the Ki-67
2 fraction
(Figure 5C), there were more cells positive for T-bet/GATA-3/
RORct (Panel D; 48.1967.95%) than cells positive for T-bet/
RORct/FOXP3 (Panel E; 31.8867.01%). Taken together, these
data suggests that Th cells co-expressing multiple transcription
factors can be both actively proliferating or resting cells.
Relationship between Th Cell Subsets and Clinical
Parameters in Asthmatics
To evaluate the possible clinical importance of the subsets
analysed, both single expressing and co-expressing Th cells were
compared to clinical parameters in the asthmatic subjects, using
a Pearson correlation test. Each subset was tested against the
main clinical asthma characteristics including FeNO, FEV1%
predicted, FEV1 reversibility, and sputum-eosinophils. The
highest correlation score (R=0.760; p,0.0005) between any
cell subset and any of the clinical parameters was single
expressing GATA-3
+ cells versus FEV1 reversibility. In addition,
two more GATA-3 subsets, T-bet
+GATA-3
+ and T-bet
+GATA-
3
+FOXP3
+, showed correlation to FEV1 reversibility (Table 3).
Furthermore, FeNO correlated to single expressing RORcti n
addition to two additional RORct subsets, T-bet
+RORct
+ and
RORct
+FOXP3
+ cells (Table 3). However, when performing
the correlation test using the subgroups of asthmatics EOS high
and EOS low, only five of the subsets in the EOS high group
showed significant correlation to FeNO or FEV1 reversibility
and none in the EOS low group (Table 3), which implies that
Figure 3. Confocal microscopy showing co-expression of
transcription factors. The three columns represent immunostained
cells from fresh ex vivo CD4-enriched cells (1
st column), CD4-enriched
cells in vitro in medium alone (2
nd column) or after stimulation with
anti-CD3/anti-CD28 antibodies (3
rd column) for 48 hours respectively.
Row A, C, E and G are samples from one non-asthmatic control subject.
Row B, D, F and H are sample from an asthmatic individual with
elevated blood eosinophils. Cells were stained with DAPI (blue nuclear
staining) and transcription factors T-bet (Th1), GATA-3 (Th2), RORct
(Th17) and FOXP3 (Treg). A+B shows co-expression of T-bet/GATA-3;
C+D, T-bet/RORct; E+F, FOXP3/GATA-3; G+H, FOXP3/RORct.
doi:10.1371/journal.pone.0040012.g003
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Parameter Healthy controls Asthmatics EOS High Asthmatics EOS Low
Mean (±SEM) Mean (±SEM) Mean (±SEM)
n=5 n=7 n=6
Medium Stim. Medium Stim. Medium Stim.
T-bet
+ GATA-3
2 RORct
2 FOXP3
2 0.13 (0.03) 0.23 (0.04) 0.11 (0.03) 0.20 (0.04)* 0.10 (0.02) 0.28 (0.09)
T-bet
2 GATA-3
+ RORct
2 FOXP3
2 0.03 (0.01) 0.15 (0.04)* 0.01 (0.00) 0.17 (0.02)*** 0.02 (0.00) 0.18 (0.02)**
T-bet
2 GATA-3
2 RORct
+ FOXP3
2 0.69 (0.16) 6.06 (1.57)* 1.02 (0.25) 5.58 (0.80)** 0.54 (0.10) 5.43 (0.81)**
T-bet
2 GATA-3
2 RORct
2 FOXP3
+ 0.49 (0.10) 0.49 (0.12) 0.63 (0.15) 0.43 (0.05) 0.70 (0.16) 0.40 (0.06)
T-bet
+ GATA-3
+ RORct
2 FOXP3
2 0.01 (0.00) 0.06 (0.01)** 0.00 (0.00) 0.08 (0.02)** 0.00 (0.00) 0.08 (0.02)**
T-bet
+ GATA-3
2 RORct
+ FOXP3
2 1.21 (0.21) 25.6 (3.66)** 1.79 (0.42) 16.78 (2.42)** 1.14 (0.16) 19.41 (2.76)**
T-bet
+ GATA-3
2 RORct
2 FOXP3
+ 0.11 (0.06) 0.10 (0.04) 0.13 (0.07) 0.07 (0.02) 0.13 (0.05) 0.08 (0.02)
T-bet
2 GATA-3
+ RORct
+ FOXP3
2 0.09 (0.03) 2.19 (0.43)* 0.12 (0.04) 3.30 (0.57)** 0.07 (0.02) 2.66 (0.34)**
T-bet
2 GATA-3
+ RORct
2 FOXP3
+ 0.02 (0.00) 0.07 (0.02) 0.03 (0.01) 0.07 (0.01)** 0.03 (0.01) 0.06 (0.01)
T-bet
2 GATA-3
2 RORct
+ FOXP3
+ 2.04 (0.62) 3.52 (0.55) 1.55 (0.28) 3.39 (0.51)** 1.20 (0.18) 3.28 (0.48)*
T-bet
+ GATA-3
+ RORct
+ FOXP3
2 0.37 (0.14) 21.24 (3.86)** 0.38 (0.16) 30.29 (2.82)*** 0.25 (0.08) 27.74 (3.06)***
T-bet
+ GATA-3
+ RORct
2 FOXP3
+ 0.01 (0.00) 0.02 (0.01)* 0.01 (0.00) 0.02 (0.00) 0.01 (0.00) 0.02 (0.00)
T-bet
+ GATA-3
2 RORct
+ FOXP3
+ 2.74 (0.76) 17.48 (2.89)** 2.32 (0.40) 14.57 (3.16)* 2.10 (0.33) 16.06 (2.57)**
T-bet
2 GATA-3
+ RORct
+ FOXP3
+ 0.11 (0.04) 1.20 (0.24)* 0.12 (0.02) 1.57 (0.22)*** 0.06 (0.01) 1.49 (0.19)**
T-bet
+ GATA-3
+ RORct
+ FOXP3
+ 0.19 (0.03) 8.32 (1.83)* 0.23 (0.05) 12.95 (2.52)** 0.17 (0.06) 11.79 (1.98)**
Values are expressed as percent of CD4
+ T cells.
*P,0.05.
**P,0.01.
***P,0.001 in comparison to medium alone.
Stim. = stimulated. Medium = medium alone.
Bold lettering highlights the transcription factor of interest.
doi:10.1371/journal.pone.0040012.t002
Figure 4. Th cells increase after in vitro TCR stimulation. Three subsets of Th cells displayed fold change differences between the study groups:
single expressing GATA-3
+, co-expressingT-bet
+GATA-3
+ and GATA-3
+RORct
+FOXP3
+, after 48 hours in vitro stimulation with anti-CD3/anti-CD28
antibodies. Data are expressed as mean6SEM. *p,0.05.
doi:10.1371/journal.pone.0040012.g004
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asthma subgroups.
Discussion
This study shows for the first time, using flow cytometry and
confocal microscopy, that circulating Th cells can be classified into
at least two main categories; those that express only one of the
master regulatory transcription factors: T-bet, GATA-3, FOXP3,
or RORct or those that co-express two or more of these
transcription factors. These findings indicate that many circulating
Th cells, in both asthmatics and healthy controls; express multiple
transcription factors which support the concept that individual Th
cells may have multiple functions in vivo in humans. However, from
Figure 5. Proliferating CD4
+CD25
+ cells expressing multiple transcription factors in fresh ex vivo whole blood from healthy non-
asthmatic controls (n=5). Antibody panel D: stained simultaneously with Ki-67/T-bet/GATA-3/RORct. Antibody panel E: Ki-67/T-bet/RORct/FOXP3.
A) Percentage of Ki-67
+ (open bar) and Ki-67
2 (filled bar) CD4
+CD25
+ cells. B) Percentage of CD4
+CD25
+Ki-67
+ expressing $ three transcription factors
(open bar) or #three transcription factors (filled bar). C) Percentage of CD4
+CD25
+Ki-67
2 expressing $ three transcription factors (open bar) or
#three transcription factors (filled bar). Data are expressed as mean6SEM.
doi:10.1371/journal.pone.0040012.g005
Table 3. Relationship between Th cell subsets and clinical parameters in asthmatics.
Asthmatics
Pearson correlation
(R value) P value
No. of
participants
FeNO T-bet
2 GATA-3
2 RORct
+ FOXP3
2 0.478 0.021 23
T-bet
+ GATA-3
2 RORct
+ FOXP3
2 0.478 0.021 23
T-bet
2 GATA-3
2 RORct
+ FOXP3
+ 0.482 0.020 23
FEV1% reversibility T-bet
2 GATA-3
+ RORct
2 FOXP3
2 0.760 0.0005 22
T-bet
+ GATA-3
+ RORct
2 FOXP3
2 0.591 0.004 22
T-bet
+ GATA-3
+ RORct
2 FOXP3
+ 0.554 0.007 22
EOS high asthmatics
FeNO T-bet
2 GATA-3
2 RORct
+ FOXP3
2 0.763 0.006 11
T-bet
+ GATA-3
2 RORct
+ FOXP3
2 0.711 0.014 11
T-bet
2 GATA-3
2 RORct
+ FOXP3
+ 0.669 0.024 11
FEV1% reversibility T-bet
2 GATA-3
+ RORct
2 FOXP3
2 0.868 0.001 10
T-bet
+ GATA-3
+ RORct
2 FOXP3
2 0.651 0.042 10
T-bet
+ GATA-3
+ RORct
2 FOXP3
+ 0.599 ns 10
EOS low asthmatics
FeNO T-bet
2 GATA-3
2 RORct
+ FOXP3
2 0.084 ns 12
T-bet
+ GATA-3
2 RORct
+ FOXP3
2 0.032 ns 12
T-bet
2 GATA-3
2 RORct
+ FOXP3
+ 0.317 ns 12
FEV1% reversibility T-bet
2 GATA-3
+ RORct
2 FOXP3
2 20.295 ns 12
T-bet
+ GATA-3
+ RORct
2 FOXP3
2 20.493 ns 12
T-bet
+ GATA-3
+ RORct
2 FOXP3
+ 20.036 ns 12
Bold lettering highlights the transcription factor of interest.
doi:10.1371/journal.pone.0040012.t003
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expressing GATA-3 cells were upregulated in asthmatics com-
pared to controls upon stimulation.
Until recently, Th cells expressing a master regulatory
transcription factor were considered to be lineage-committed cells
with particular characteristics, including the release of defined
cytokines. This dogma has recently been questioned, by several
studies that suggest T cells can exhibit functional plasticity in vitro
[8–12]. Furthermore, it is likely that the multi-transcription factor
Th cells are not naı ¨ve, as the present study shows that they express
CD25, arguing that the cells have been activated. Although the
possibility of recent cell activation cannot be excluded [20], the
participants recruited into the study were not undergoing any
asthma exacerbations, and their symptoms were stable.
Sub-analysis of the T-bet, GATA-3, FOXP3, and RORct cell
populations, enabled up to 15 different populations to be defined.
Thesepopulationsexpressedsingletranscriptionfactorsoruptofour
transcription factors, arguing for the presence of Th cell plasticity in
humans as has been earlier proposed from animal models or in vitro
[14–18]. The strength of this current study is that these cells were
detectedinfreshbloodobtainedwithinonehourofsampling,without
any form of artificial manipulation. To date, this is the first study
showing that circulating Th cells co-express several transcriptions
factors,whichareconsideredtofunctionasmasterregulators.These
resultsraiseinterestingquestionslike;whatisthefunctionoftheseco-
expressing Th cells, and which transcription factor is dominant?
These questions were beyond the scope of this study, but data from
other in vitro studies suggest that they may have multiple functions.
Voo et al recently showed that FOXP3
+ interleukin (IL)-17
+ cells
expressing RORct still showed suppressive function in vitro [21].
Furthermore,animalstudieshaveshownthatT-betinductioninTreg
cells, after infection, facilitated these cells to supress Th1 inflamma-
tion [22,23]. Furthermore, in a model of non-allergic chronic lung
inflammation, lung tissue CD4
+IL-17
+IL-13
+IL-4
+ cells co-ex-
pressed RORct and GATA-3 after local or systemic immunization
with inflammatory dendriticcells [24].
The only subset that was different after sub-analysis was single
FOXP3 cells, which was increased only in EOS high asthmatics
compared to controls. Increased Tregs in asthmatics has
previously been shown [25]. On the contrary, there are also
studies [26,27] observing decreased FOXP3 expression in
asthmatics. However, these investigators looked at a different cell
population as they estimated the CD4
+CD25
high cells that
expressed FOXP3 and did not address the co-expression with
others transcription factors [26,27].
After 48 hours of non-specific CD3/CD28-activation in vitro,a
substantial increase in the number of Th cells expressing multiple
transcription factors was observed. Moreover, only a small percent-
age of stimulated cells were found to express a single transcription
factor. This strongly argues that circulating Th cells, expressing a
masterregulatorytranscriptionfactorsuchasGATA-3alsohavethe
capacity to express additional transcription factors upon further
stimulation. The question remains unanswered, of whether Th cells
thatco-expressmultipletranscriptionfactorsareundergoinglineage
commitment, or whether an already committed cell can express
multiplemastertranscriptionfactors(Figure6).Severalstudieshave
investigated the co-expression of other key regulatory transcription
factorsinFOXP3
+Tregs.GATA-3expressioninTregsisproposedto
Figure 6. Alternative models for multiple transcription factor Th cells (Multi-TF). A) Multiple transcription factor cells are between naı ¨ve
and terminally differentiated cells. B) Multiple transcription factor cells are differentiated cells that are transitioning from one cell type to another,
going through a stage of multi expression before reaching the new type.
doi:10.1371/journal.pone.0040012.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e40012be a default response to TCR stimulation under neutral conditions,
while under inflammatory settings, GATA-3 expression in Tregs
limits the expression of transcription factors associated with T cell
differentiation[17].Themicroenvironmentmayhaveanimportant
role for the balance of co-expression e.g T cells receiving a TGF-b
signalcanacquirethepotentialtodevelopintoeitherTregsorTh17
cells. In the absence of pro-inflammatory cytokines FOXP3 inhibits
RORct,butinthepresenceofthesecytokinestheoppositeoccur[18].
As in vitro studies showing that progenitor cells unable to
proliferate remain uncommitted and bipotent, expressing both T-
bet and GATA-3 mRNA in response to polarising signals for
maturation [28] this study combined the transcription factor
staining with a marker for proliferation, Ki-67. Interestingly, the
data shows that actively proliferating cells co-express multiple
transcription factors ex vivo to a great extent, at least in healthy
control subjects. Furthermore, the present study is the first to
confirm this co-expression of multiple transcription factors at the
protein and single cell level in humans.
The population of this study was selected based on the number
of circulating eosinophils, as the scope was to evaluate several
transcription factors in an eosinophilic asthma phenotype.
However, patients with elevated eosinophils within the normal
range were chosen, as the aim was to study stable mild/moderate
asthmatics without a ‘‘heavy’’ Th2 polarisation. It was surprising
that no differences were detected in the total number of GATA-3
expressing CD4 cells, as this is considered the master transcription
factor most related to eosinophilia [29]. However, upon TCR
stimulation, only asthmatics showed upregulated GATA-3 cell
subsets, arguing for a shift in this transcription factor. Further-
more, when a correlation test was applied between transcription
factors and major clinical characteristics, the strongest correlations
were found between GATA-3 and FEV1 reversibility, a key
characteristic of asthma.
This study contains a relatively low number of asthmatics who
were in a stable phase of disease, which may affect the results.
Although beyond the scope of this study, analysis of single
transcription factor and multi-transcription factor cells resident in
the tissue of both control subjects, as well as asthmatics, would be
of great interest in understanding the role in disease progression.
In summary, it has been demonstrated for the first time, that in
both healthy individuals and individuals with mild/moderate
stable asthma there are circulating Th cells expressing several
transcription factors. This data argues against the key importance
of a single transcription factor in stable asthma patients. However,
TCR stimulation increased the GATA-3 cell populations, most
profoundly in asthmatics. Furthermore, GATA-3 expression in
fresh samples was correlated with FEV1 reversibility, a main
feature of asthma.
Supporting Information
Figure S1 Flow cytometry analysis of Th cell subsets.
Representative FACS contour plots (level 10%) showing
CD4
+CD25
+ cells gated for T-bet (Th1), GATA-3 (Th2), RORct
(Th17) and FOXP3 (Treg). One individual from each group is
presented in the top three rows. In the final row, the fluorescence
minus one (FMO) control used for analyses is shown.
(TIF)
Figure S2 Technical controls for confocal microscopy. Z
sectioning is not performed on the following samples. Micrographs
of ex vivo samples: 1) Only DAPI staining; 2) DAPI/mIgG1isotype
control (IC)/Goat anti-mouse IgG-AF555; 3) DAPI/ratIgG2a IC/
Goat anti-rat IgG-AF488; 4) DAPI/ratIgG2b IC/Goat anti-rat
IgG-AF488; 5) DAPI/No primary antibody/Goat anti-mouse
IgG-AF555/Goat anti-rat IgG-AF488; 6) DAPI/mouse anti-
human FOXP3/Goat anti-mouse IgG-AF555; 7) DAPI/mouse
anti-human T-bet/Goat anti-mouse IgG-AF555; 8) DAPI/Rat
anti-human GATA-3/Goat anti-rat IgG-AF488; 9) DAPI/Rat
anti-human RORct/Goat anti-rat IgG-AF488; Micrographs of in
vitro samples: 10) DAPI/mIgG1IC/Goat anti-mouse IgG-AF555
(medium alone); 11) DAPI/mIgG1IC/Goat anti-mouse IgG-
AF555 (stimulated); 12) DAPI/ratIgG2a IC/Goat anti-rat IgG-
AF488 (medium); 13) DAPI/ratIgG2a IC/Goat anti-rat IgG-
AF488 (stim.); 14) DAPI/ratIgG2b IC/Goat anti-rat IgG-AF488
(medium); 15) DAPI/ratIgG2b IC/Goat anti-rat IgG-AF488
(stim.); 16) DAPI/No primary antibody/Goat anti-mouse IgG-
AF555/Goat anti-rat IgG-AF488 (medium); 17) DAPI/No
primary antibody/Goat anti-mouse IgG-AF555/Goat anti-rat
IgG-AF488 (stim.); 18) DAPI/mouse anti-human FOXP3/Goat
anti-mouse IgG-AF555 (medium); 19) DAPI/mouse anti-human
FOXP3/Goat anti-mouse IgG-AF555 (stim.); 20) DAPI/mouse
anti-human T-bet/Goat anti-mouse IgG-AF555 (medium); 21)
DAPI/mouse anti-human T-bet/Goat anti-mouse IgG-AF555
(stim.); 22) DAPI/Rat anti-human GATA-3/Goat anti-rat IgG-
AF488 (medium); 23) DAPI/Rat anti-human GATA-3/Goat anti-
rat IgG-AF488 (stim.); 24) DAPI/Rat anti-human RORct/Goat
anti-rat IgG-AF488 (medium); 25) DAPI/Rat anti-human
RORct/Goat anti-rat IgG-AF488 (stim.).
(TIF)
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